Meeting
2023 ASCO Annual Meeting
Interim results of a phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma.
Authors
Neal Shiv Chawla
City of Hope Comprehensive Cancer Center, Duarte, CA
Neal Shiv Chawla , Nadezhda Omelchenko , Elan Younesi , Chrysler Valencia , Amir Ahari , Ania Moradkhani , Victoria Chua , Don Brigham , Sant P. Chawla , Erlinda Maria Gordon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT# 03886311
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 11556)
DOI
10.1200/JCO.2023.41.16_suppl.11556
Abstract #
11556
Poster Bd #
490
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.
First Author: Makoto Ueno
Poster
A phase 2 study of talimogene laherparepvec, nivolumab, and trabectedin (TNT) in advanced sarcoma.
First Author: Neal Shiv Chawla
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of a combination of sintilimab, bevacizumab plus gemcitabine, and albumin-bound paclitaxel for initially unresectable gallbladder carcinoma: A prospective, single-arm phase II study.
First Author: Miao Wang
Poster
2022 ASCO Annual Meeting
Efficacy and safety of nivolumab for locally advanced or metastatic cutaneous cell carcinoma (NIVOSQUACS trial).
First Author: Roland Lang